









市場行情
/
股票
/
nasdaq-spro
/

Spero Therapeutics Inc

SPRO

2.370USD

+0.050+2.16%

交易中（美東）報價延遲15分鐘

133.46M總市值

虧損本益比TTM



Spero Therapeutics Inc

2.370

+0.050+2.16%

概覽公司財務分析

概覽

公司

財務

分析

關於 Spero Therapeutics Inc 公司

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

Spero Therapeutics Inc簡介



公司代碼SPRO

公司名稱Spero Therapeutics Inc

上市日期Nov 02, 2017

CEORajavelu (Esther)

員工數量32

證券類型Ordinary Share

年結日Nov 02

公司地址675 Massachusetts Ave Ste 14

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02139-3309

電話18572421600

網址https://sperotherapeutics.com/

公司代碼SPRO

上市日期Nov 02, 2017

CEORajavelu (Esther)

Spero Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Ankit Mahadevia, M.D.

Non-Executive Director

364.22K

-1.77%

Ms. Esther Rajavelu

President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer

188.41K

-17.61%

Mr. Timothy (Tim) Keutzer

Chief Operating Officer

145.31K

-1.15%

Dr. Milind S. Deshpande, Ph.D.

Independent Director

91.45K

+27.99%

Ms. Kathleen Tregoning

Independent Director

75.00K

+36.36%

Ms. Cynthia Smith

Independent Director

75.00K

+36.36%

Mr. Frank E. Thomas, CPA

Independent Chairman of the Board

75.00K

+36.36%

Dr. Patrick Volkert Jozef Johannes Vink, M.D.

Lead Independent Director

Mr. Scott T. Jackson

Independent Director

Dr. John C. Pottage, Jr., M.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Ankit Mahadevia, M.D.

Non-Executive Director

364.22K

-1.77%

Ms. Esther Rajavelu

President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer

188.41K

-17.61%

Mr. Timothy (Tim) Keutzer

Chief Operating Officer

145.31K

-1.15%

Dr. Milind S. Deshpande, Ph.D.

Independent Director

91.45K

+27.99%

Ms. Kathleen Tregoning

Independent Director

75.00K

+36.36%

Ms. Cynthia Smith

Independent Director

75.00K

+36.36%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

業務USD

名稱

營收

佔比

Collaboration Revenue Related Party

11.80M

83.18%

Grant Revenue

2.39M

16.82%

Collaboration Revenue

0.00

0.00%

地區USD

名稱

營收

佔比

United States

14.19M

100.00%

業務

地區

業務USD

名稱

營收

佔比

Collaboration Revenue Related Party

11.80M

83.18%

Grant Revenue

2.39M

16.82%

Collaboration Revenue

0.00

0.00%

股東統計

更新時間: 12月2日週二

持股股東

股東類型

持股股東

佔比

GSK plc

16.31%

Pfizer Inc

4.19%

The Vanguard Group, Inc.

3.53%

Anson Funds Management LP.

2.85%

Renaissance Technologies LLC

2.58%

其他

70.54%

持股股東

佔比

GSK plc

16.31%

Pfizer Inc

4.19%

The Vanguard Group, Inc.

3.53%

Anson Funds Management LP.

2.85%

Renaissance Technologies LLC

2.58%

其他

70.54%

股東類型

持股股東

佔比

Corporation

20.51%

Hedge Fund

6.15%

Investment Advisor

5.58%

Investment Advisor/Hedge Fund

2.52%

Individual Investor

2.43%

Venture Capital

1.64%

Research Firm

0.20%

Bank and Trust

0.02%

其他

60.96%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

106

9.05M

16.08%

-5.89M

2025Q2

114

26.06M

46.61%

-2.84M

2025Q1

116

27.38M

49.07%

-1.56M

2024Q4

125

27.51M

50.50%

+2.91M

2024Q3

143

24.19M

44.62%

-8.19M

2024Q2

160

25.74M

47.53%

-7.31M

2024Q1

203

25.36M

47.08%

-8.60M

2023Q4

209

24.88M

47.35%

-1.62M

2023Q3

223

24.62M

47.01%

-2.06M

2023Q2

230

24.99M

47.83%

-1.96M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

GSK plc

9.19M

16.33%

Mar 27, 2025

Pfizer Inc

2.36M

4.2%

Jun 30, 2025

The Vanguard Group, Inc.

1.95M

3.47%

+186.76K

+10.59%

Jun 30, 2025

Anson Funds Management LP.

1.62M

2.87%

-2.18M

-57.48%

Jun 30, 2025

Renaissance Technologies LLC

832.16K

1.48%

-138.74K

-14.29%

Jun 30, 2025

Alphabet, Inc.

889.98K

1.58%

Jun 30, 2025

Geode Capital Management, L.L.C.

510.70K

0.91%

-14.17K

-2.70%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

433.55K

0.77%

-39.27K

-8.31%

Jun 30, 2025

Mahadevia (Ankit)

364.22K

0.65%

-6.57K

-1.77%

Aug 28, 2025

The Informed Momentum Company LLC

239.14K

0.42%

+239.14K

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Invesco NASDAQ Future Gen 200 ETF

0.63%

Avantis US Small Cap Equity ETF

iShares Micro-Cap ETF

Invesco NASDAQ Future Gen 200 ETF

佔比0.63%

Avantis US Small Cap Equity ETF

佔比0%

iShares Micro-Cap ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Spero Therapeutics Inc的前五大股東是誰？



Spero Therapeutics Inc的前五大股東如下：
GSK plc
持有股份：9.19M
佔總股份比例：16.33%。
Pfizer Inc
持有股份：2.36M
佔總股份比例：4.20%。
The Vanguard Group, Inc.
持有股份：1.95M
佔總股份比例：3.47%。
Anson Funds Management LP.
持有股份：1.62M
佔總股份比例：2.87%。
Renaissance Technologies LLC
持有股份：832.16K
佔總股份比例：1.48%。